Phase Ⅲ Clinical Trial of an Inactivated Hepatitis A Vaccine

NCT07793227 on ClinicalTrials.gov Phase 3 Sinovac Biotech Co., Ltd (industry) Started 2026-08-20 Recruiting

Among the lowest-risk 1% of active trials

Model scores of the 29,894 trials active now.

Model score 2% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 17% of the time (213 trials).

Active trial: scored by the current model, trained on trials that started 2008–2014.

The next 2 years and beyond

2% chance of termination in the next 2 years, given it has been running 0.1 years: higher than 1% of running trials over the same window.

Cumulative chance of ending terminated (red) or completed (green) by each year from now, given it is still running today. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

What moved the score

Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: priortherapycelltrialto screening
Phrases that lowered it: vaccinevaccinationhealthyparticipantsvaccines
Accepts healthy volunteers: Yes (lowers risk) · Who can join
Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
Primary purpose: prevention (lowers risk) · Design
Phase: 3 (lowers risk) · Design
Number of arms: 5 (lowers risk) · Design
Drug's FAERS reports with a death: 7.5% (lowers risk) · Drug's FDA history
Trials the sponsor started in the prior 2 years: 17 (lowers risk) · Sponsor's track record
Disease area, cancer: No (lowers risk) · Disease area
Has a data monitoring committee: No (lowers risk) · Design
Sponsor type: industry (lowers risk) · Sponsor's track record
Design: parallel (raises risk) · Design
Minimum age: 1 (lowers risk) · Who can join
Blinding: quadruple (lowers risk) · Design
Sponsor's past trials: 56 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

The trial

Design

Phase: 3 (typical: 2)
Number of arms: 5 (typical: 2)
Allocation: randomized
Design: parallel
Primary purpose: prevention (typical: treatment)
Blinding: quadruple (typical: none)
Has a data monitoring committee: No (typical: 56% yes)
Responsible party: sponsor
Collaborators: 1 (typical: 0)
Keywords listed: 3 (typical: 1)

Who can join

Minimum age: 1 (typical: 18)
Maximum age: not given (typical: 71)
Sex: all
Accepts healthy volunteers: Yes (typical: 9% yes)

Sponsor's track record

Sponsor type: industry (typical: academic or other)
Sponsor's past trials: 56 (typical: 32)
Sponsor's past termination rate: 0% (typical: 9.9%)
Trials the sponsor started in the prior 2 years: 17 (typical: 19)

Drug's FDA history

Drugs with FDA adverse-event history: 1
Drug has FAERS history: Yes (typical: 64% yes)
Drug's FAERS reports before start: 106 (typical: 2148)
Drug's FAERS reports in the prior 12 months: 27 (typical: 412.5)
Drug's FAERS reports marked serious: 80.2% (typical: 85.6%)
Drug's FAERS reports with a death: 7.5% (typical: 15.9%)

Disease area and drugs

Disease areas: digestive
Drugs matched to FDA substances: hepatitis a vaccine inactivated

Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.

Similar finished trials

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine NCT03525119 · started 2018 · scored riskier than 1% of active trials completed
A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate NCT05727267 · started 2024 · scored riskier than 2% of active trials completed
To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A) NCT03654677 · started 2017 · scored riskier than 1% of active trials completed
Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults NCT01250795 · started 2010 · scored riskier than 1% of active trials completed
Clinical Trial of Recombinant Hepatitis B Vaccine (Hansenula Polymorpha, 10μg) NCT04075201 · started 2019 · scored riskier than 1% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.